At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Sulfur hexafluoride type-a lipid microspheresdrug
Likely dose
Sulfur hexafluoride type-a lipid microspheres (contrast agent for renal ultrasound)AI-extracted
Key inclusion· 5
- ✓Age 8 years or older
- ✓History of urinary tract infection (UTI)
- ✓Prior Voiding Cystourethrogram (VCUG) documenting vesicoureteral reflux
- ✓Candidate for DMSA scan or renal scar imaging
Key exclusion· 10
- ✕Age less than 8 years
- ✕Allergy to contrast or related products
- ✕Cardiac shunt or congenital heart anomalies
- ✕Abnormal baseline ECG
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
In Brief
A Phase 2 clinical trial evaluating Sulfur hexafluoride type-a lipid microspheres for Urinary Tract Infection and Vesicoureteral Reflux. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infection, Vesicoureteral Reflux
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedJun 2016
Primary CompletionNov 2016
TodayJul 2026
First PostedJun 1, 2016
Enrollment StartMar 1, 2016
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.1 years ago
Interventions
Sulfur hexafluoride type-a lipid microspheresdrug
Used as a contrast to enhance renal ultrasound